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When a lot of remedies are suggested for a 
disease, that means it can’t be cured. 
(The Cherry Orchard, Anton Chekhov) 
Introduction 
Obstructive sleep apnoea (OSA) is now recog- 
nized as the most important cause of sleep 
disturbance with daytime sleepiness. The pri- 
mary pathophysiologic event in OSA is upper 
airway occlusion during sleep resulting in tran- 
sient asphyxia and frequent arousals to restore 
airway patency. 
It is only recently that the high prevalence of 
OSA has been appreciated. The prevalence of 
sleep apnoea in the middle-aged work force is 
estimated at 4% for men and 2% for women (1). 
It has been reported to be as high as 46% in 
commercial truck drivers (2). The National 
Commission on Sleep Disorders Research esti- 
mates that 18 million Americans are afflicted 
with OSA (3). 
Concomitant with the recognition of the 
increased prevalence of the disorder, OSA is now 
considered a major public health concern (4). In 
one retrospective study, the cumulative 8 yr mor- 
tality of untreated sleep apnoea was 37% for 
patients with an apnoea index greater than 20, 
Correspondence should be addressed to: L. S. Aboussouan, 
Harper Hospital, 3-Hudson, 3990 John R, Detroit, 
MI 48201, U.S.A. 
0954-6111/97/040181+ 11 $12.00/O 
compared to 4% for those with an index at or 
below 20 (5). Increased cardiovascular morbidity 
(6,7) and traffic accidents (8,9) are potential 
reasons. Although hypertension in patients with 
OSA is often confounded by the presence of 
obesity and increased age (lo), recent data impli- 
cate sleep apnoea as an independent contribu- 
tor to the development of hypertension (11,12). 
The National Commission on Sleep Disorders 
Research estimates that sleep apnoea may be 
responsible for 38 000 cardiovascular deaths 
per year (3). In addition, the estimated annual 
cost of OSA to society is $42 million from 
hospitalization alone (3). 
Despite the high prevalence, cost to society, 
and serious morbidity and mortality, as many as 
95% of OSA patients may be undiagnosed (3). 
This is particularly important in that there are 
several available treatment options. Physicians 
should maintain a high index of suspicion to 
appropriately identify and refer patients at risk. 
The following discussion will focus on the 
diagnostic and therapeutic options in OSA 
with emphasis on their limitations. 
Diagnosis 
A careful history and physical examination are 
essential. Particular attention should be given to 
the evaluation of women since they are less likely 
to report symptoms and may have symptoms 
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without morbid obesity (13). The clinical evalu- 
ation, however, has significant limitations and 
cannot serve as a reliable screening test. For 
example, a subjective evaluation (based on a 
history and a physical examination) identifies 
only 52% of OSA patients (with a specificity of 
70%) (14). Similarly, bedside observation by 
physicians identifies only 64% of OSA patients 
(although 100% specific) (15). Models of logistic 
regression analysis have improved the detection 
of this disorder. These models, derived from 
clinical data, have a sensitivity greater than 90%, 
and may result in a reduction in the need for 
sleep studies by one-third (14,16,17). Although 
comprehensive models have superior predictive 
powers for the diagnosis of OSA, a four-variable 
step-wise selection model was found to have the 
advantage of simplicity; this latter model incor- 
porates a measurement of neck circumference 
and presence of hypertension as the most signifi- 
cant independent predictors of apnoea severity 
(the other two variables being habitual snoring 
and partner report of nocturnal choking or 
gasping) (17). 
Previously, a saw-tooth appearance on the 
flow-volume curve was believed to be character- 
istic of sleep apnoea. This is now recognized as a 
poorly sensitive test (18), and a non-specific 
marker for upper airway obstruction (19). An 
ambulatory device that monitors oxygen satu- 
ration, heart rate, snoring and body position 
was found to have a high sensitivity and speci- 
ficity for sleep apnoea, and may be used as a 
low-cost screening tool (20). Logistic regression 
(14,16,17), measurement of neck girth (17,21), 
cephalometric data (22), acoustic analysis 
(23,24) and ambulatory devices (20) can all 
supplement the clinical suspicion. However, an 
inherent limitation in most of these techniques is 
that events occurring during sleep are inferred 
from data gathered in the wakeful state. There- 
fore, the preferred diagnostic modality remains 
to be overnight polysomnography. 
Overnight polysomnography is the most 
accepted study in the evaluation of sleep-related 
breathing disorders despite certain limitations. 
For instance, there is significant night-to-night 
variability in the apnoea index, particularly in 
patients with mild OSA (defined as less than 100 
apnoeas per night) (25). A potential but partial 
cause for this variability may be body position- 
ing (26). One overnight polysomnogram should 
suffice, and usually identifies OSA in 94% of 
subjects that would be detected by two consecu- 
tive overnight studies (27). A repeat study on the 
consecutive night may be positive in about 50% 
of patients strongly suspected of having OSA, 
and with a negative first night polysomnogram 
(27,28). 
Other related clinical scenarios warrant recog- 
nition. The newly described upper airway resist- 
ance syndrome has been associated with daytime 
hypersomnia and frequent arousal from sleep 
detected. by electroencephalogram (EEG) moni- 
toring in relation to increased upper airway 
resistance documented by recordings of intra- 
oesophageal pressure (29). Sleep apnoea has also 
been reported following heart transplantation 
(30), lung transplantation (31) and in association 
with negative-pressure ventilation (32,33). 
Treatment 
MEDICAL PHARMACOLOGIC 
Pharmacological approaches to the treatment of 
OSA have certain appeal. A safe and effective 
drug would be preferred to surgery or cumber- 
some mechanical devices in mild or moderate 
sleep apnoea, and may be more cost-effective. 
Unfortunately, the many drugs used have had 
narrow therapeutic windows, unacceptable 
side-effects and indirect modes of action. 
Medications may address some pathophysio- 
logic mechanisms of OSA by effecting modifi- 
cations in sleep stage distribution, improvement 
in ventilatory drive, control of central apnoeas, 
or stabilization of the collapsible airway. Pre- 
clinical testing of pharmacologic interventions 
should incorporate the present state of knowl- 
edge in upper airway physiology (34). The ideal 
drug would be a respiratory stimulant which 
preferentially increases the tone of appropriate 
pharyngeal muscles (34). Specifically, selective 
enhancement of upper airway muscle tone may 
result in improvement of OSA. 
Rapid eye movement (REM) sleep is charac- 
terized by hypotonia of the upper airway 
muscles, and as a result, obstructive sleep events 
are more profound during this stage. Most 
common anti-depressants (including tricyclic 
compounds, monoamine oxidase inhibitors and 
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serotonin uptake inhibitors) suppress REM 
sleep. These agents may, therefore, benefit the 
patient with apnoeas occurring predominantly 
during REM sleep. For instance, protryptiline 
has been shown to decrease apnoeas by 
diminishing REM sleep (35). However, REM 
sleep is already reduced in OSA, and protryp- 
tiline may further disrupt sleep architecture. 
Moreover, it may result in cardiac arrhythmias 
and anti-cholinergic side-effects necessitating 
discontinuation in up to 50% of patients. 
In some patients, there is associated daytime 
alveolar hypoventilation. Appropriate studies 
identify the occasional patient with hypo- 
thyroidism for whom specific therapy with 
thyroxine may resolve OSA. In the absence 
of hypothyroidism, progestational agents have 
been shown to increase alveolar ventilation and 
hypercapnic ventilatory chemosensitivity. These 
agents may be of particular use in postmeno- 
pausal women. However, medroxyprogesterone 
appears to have no rule in the treatment of 
normocapnic patients with OSA (36), and does 
not alter indices of severity of OSA even in the 
hypercapnic patient (37). 
Some agents such as acetazolamide and sali- 
cylates may stabilize the upper airway walls by 
increasing respiratory drive. However, in one 
study, acetazolamide has been shown to worsen 
OSA (38). The applicability of acetazolamide 
may be limited to patients with Cheynes-Stokes 
breathing pattern or central apnoeas (39). A 
canine model has found salicylates to be useful 
in dosages resulting in supratherapeutic serum 
levels that may hamper clinical use (40). 
Serotonin has been found to increase the tonic 
excitatory drive to hypoglossal motor neurons 
in decerebrate cats, and therefore may increase 
upper airway muscle tone or phasic motor 
activity (41,42). In addition, a decrease in brain 
and medullary serotonergic activity has been 
speculated in patients in OSA (42). The use of 
fluoxetine (a serotonin re-uptake inhibitor) has 
beneficial effects in some OSA patients (43). 
Alternatively, studies performed on newborn 
rats reveal that serotonin depresses the activity 
of hypoglossal motor neurons (44), and may 
precipitate obstructive apnoeas (45,46). 
Although nocturnal oxygen therapy has been 
proposed as an alternate form of treatment (47), 
it does not alleviate hypersomnolence nor 
improve pulmonary hypertension (47,483. This 
lack of described benefit of oxygen therapy on 
daytime hypersomnolence may be because 
hypersomnolence is more likely due to sleep 
fragmentation than hypoxaemia (49). 
MEDICAL NON-PHARMACOLOGIC 
Weight Lass 
As previously mentioned, the measurement of 
neck circumference is a significant independent 
predictor of apnoea severity (17). Similarly, 
magnetic resonance imaging studies have shown 
a correlation between the amount of pharyngeal 
fatty infiltration and apnoea severity (50). 
Improvement in sleep apnoea has been docu- 
mented following’ weight loss achieved either 
through dieting (51) or gastric surgery (52). 
Further, the weight loss and decrease in ap- 
noeas was associated with a marked decrease 
in pharyngeal adipose tissue (50). Therefore, 
increased adipose tissue in the neck may predis- 
pose to airway narrowing, and weight loss 
should be part of the management of the obese 
patient with OSA. A recent study casts doubt on 
the long-term effectiveness of weight reduction 
surgery in the control of sleep apnoea, perhaps 
indicating that morbid obesity is not the only 
factor in the development of OSA (53). 
Continuous Positive Airway Pressure 
Nasal continuous positive airway pressure 
(CPAP) has become the treatment of choice for 
adults with obstructive sleep apnoea. Modelling 
of the upper airway as a Starling resistor has 
allowed the determination of a critical opening 
upstream pressure below which occlusion and 
cessation of flow occur (54). Using this model, 
disorders characterized by increased resistance 
to airflow can be viewed along a continuum 
ranging from normal and progressing to asymp- 
tomatic snorers, patients with sleep hypopnoea 
and frank apnoeas (55). These would correspond 
to progressively less negative opening pressure, 
and eventually to positive opening pressure in 
cases of OSA (55). This model has the added 
advantage of providing a theoretical niche, 
between asymptomatic snoring and hypopnoea, 
for the recently described upper airway resist- 
ance syndrome. Continuous positive airway 
184 TOPICAL REVIEW 
pressure allows progressive restoration of air- 
flow, as the pressure applied is raised above the 
opening pressure (56). At the appropriate CPAP 
pressure, complete resolution of apnoeas may 
occur (56). Although the main mode of action of 
CPAP is pneumatic splinting of the collapsible 
upper airway, alternate hypotheses have in- 
cluded increased functional residual capacity 
(57), and resolution of airway oedema (58). The 
device and its use can be associated with discom- 
fort and apprehension for the patient. Recent 
studies have shown that as many as 24% of 
patients discontinue therapy (59,60). Although 
60% of users report using the device nightly, only 
46% meet strict objective criteria of regular use 
(at least 4 h of CPAP on 70% of the days 
monitored) (61). The initial response is not a 
determinant of compliance (59) although pre- 
treatment daytime sleepiness, satisfaction with 
CPAP, and awareness of beneficial effects are 
determinants (59,61,62). The initial severity of 
the disorder was a predictor of compliance in 
some studies (62,63), but not others (59). In as 
much as CPAP use appears to reduce OSA 
mortality (5), attempts at improving use and 
compliance are important. 
Bilevel positive airway pressure has been pro- 
posed as a modality to increase compliance. In 
one study, independent adjustment of expiratory 
and inspiratory pressure allowed control of 
apnoeas at lower expiratory airway pressure 
(57). Some data suggest a 67% ‘salvage’ rate with 
bilevel positive airway pressure in patients 
who had failed CPAP (64). Alternatively, a 
randomized study of CPAP vs. bilevel positive 
airway pressure found no difference between the 
two groups concerning hours of use, mask dis- 
comfort, machine noise and nasal stuffiness (65). 
However, in that same study, the initial dropout 
rate in the CPAP group was nearly double that 
in the bilevel positive airway pressure group 
(31 vs. 16%, respectively) (65). Nasal surgery 
may also improve compliance with CPAP (66). 
Customized nasal masks and nasal pillows have 
also been used to allow delivery of CPAP with 
better fit and comfort to the patient. Certain 
manufacturers of CPAP delivery systems have 
incorporated a ‘pressure ramping’ feature that 
results in a slow build-up of pressure after 
sleep onset. Whether this approach improves 
tolerance remains to be determined (67). 
Continuous positive airway pressure requires 
a repeat titration sleep study to determine the 
optimal level of airway pressure. A recently 
validated prediction equation for the level of 
necessary CPAP has been proposed to optimize 
and shorten the titration study with possible 
reduction in cost (68). Flow limitation on the 
inspiratory flow contour from a CPAP system 
suggests residual upper airway resistance (69). 
Adjusting the level of CPAP against flow con- 
tour may therefore serve as an alternate tech- 
nique of CPAP titration that requires validation 
(69). Once determined, however, optimal CPAP 
requirement may vary with body habitus or 
weight, sleep stage and alcohol intake. Ongoing 
studies on self-titrating, real-time, demand 
CPAP systems will determine whether these 
appliances control respiratory disturbances, 
relieve hypersomnia, enhance compliance, and 
reduce the need for titration studies (70,71). 
Oval Appliances 
Other conservative treatment alternatives have 
included tongue-retaining devices (72) and 
anterior mandibular positioning (73-77). Ana- 
tomic considerations usually do not predict the 
success of these appliances (78). The tongue- 
retaining device is worn during sleep, and 
increases the volume of the upper airway by 
holding the tongue forward. It is most useful in 
patients with significant positional variability in 
the severity of apnoeas (i.e. twice as severe in the 
supine position compared to the side position) 
and with body weight less than 50% above ideal 
(72). It is also favoured in patients with large 
tongues on either two-dimensional cephalo- 
metric analyses, or three-dimensional computed 
tomography reconstructions (78). Interestingly, 
the device may be useful as an adjunct to uvulo- 
palatopharyngoplasty (UPPP) in those who do 
not respond satisfactorily to the procedure (72). 
Anterior mandibular positioning using various 
intra-oral appliances has also been shown to 
reduce OSA (73-76). It has the theoretical, 
though not yet substantiated, risk of temporo- 
mandibular joint (TMJ) remodelling with conse- 
quent TMJ dysfunction (76). A review of the use 
of oral appliances reveals that 50% of treated 
patients achieve a post-treatment apnoea- 
hypopnoea index below 10, but that as many as 
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40% are left with an apnoea-hypopnoea index 
above 20 (79,80). Oral discomfort was also com- 
mon (79). Crossover studies have shown that 
anterior mandibular positioning devices are 
preferred over CPAP, although they are less 
effective (80,81). Newer devices enable the 
patient to gradually adapt to progressively 
greater degrees of prognathia over several 
months. This approach has the potential to 
improve both efficacy and compliance (82). 
Neurosiimulation of the Hypoglossal Nerve 
An innovative approach to the treatment of 
OSA has been neurostimulation of the hypo- 
glossal nerve. This technique has been shown to 
relieve partial airway obstruction in mongrel 
dogs, and to interrupt apnoeas in humans (83). 
The mechanism may be a decrease in collaps- 
ibility of the airway as reflected by measured 
decreases of the critical opening pressure (84). 
Whether these findings will have any clinical 
applications remains to be determined. 
SURGICAL 
The disappointing results of medical interven- 
tions and the recognized limitations of CPAP 
may result in renewed impetus toward surgical 
techniques in the treatment of OSA. Surgical 
correction of nasal obstruction does not result 
in an improvement in sleep apnoea (85,86), 
although it may improve CPAP compliance and 
increase REM sleep (85). Uvulopalatopharyngo- 
plasty (UPPP) was introduced in 1981 as a 
surgical alternative to tracheostomy in the treat- 
ment of OSA. The success rate of UPPP is only 
50%, even when a conservative definition of 
success is used (i.e. 50% reduction in the apnoea- 
hypopnoea index) (87). Besides the variable 
success rate, other limitations of UPPP have to 
be recognized. There is, for instance, some data 
to suggest that the benefit of UPPP may not last 
over time (88-90). Also, although some authors 
report no difference in the long-term survival 
between OSA patients treated with CPAP and 
those treated with UPPP (91) others have shown 
no accrued survival for OSA patients treated 
with UPPP compared to untreated patients with 
an apnoea index above 20 (5). A further caveat 
may be increased tolerance to nasal CPAP in 
patients with previous palatal surgery (59). 
Long-term complications of UPPP include nasal 
regurgitation and regulation of speech tone. 
Non-standardized surgical techniques (92) 
and inadequate selection of UPPP candidates 
may be partly responsible for the variability in 
success rate and the lack of apparent survival 
benefit. Patients with sites of collapse caudad to 
the oropharynx may not be expected to respond 
to UPPP which does not affect the lower or 
hypopharyngeal airway. Many tests have, there- 
fore, been proposed to help identify a subset of 
OSA patients with better expected UPPP out- 
come (Table 1) (88,89,93-105). In most of these 
studies, the selected predictor of success was a 
technique that would identify exclusive or pref- 
erential cephalad sites of obstruction (Table 1) 
(88,X9,93-105). Unfortunately, the techniques 
selected were often static or obtained in the 
wakeful state, thereby ignoring the unique 
dynamic nature of events occurring during sleep. 
As expected, the most successful techniques are 
dynamic studies in which the airway is visualized 
during sleep either through videoendoscopy (88), 
or somnofluoroscopy (Table 1) (93). Other 
studies indicate that the Mtiller manoeuvre could 
be used to exclude patients with hypopharyngeal 
collapse from UPPP (89,97). Despite this 
progress, no single method can reliably identify 
which patients will benefit from UPPP. 
First introduced in this country in 1993 for the 
treatment of primary snoring, laser-assisted 
uvulopalatoplasty (LAUP) has a lower morbid- 
ity than traditional UPPP. The efficacy of LAUP 
for sleep apnoea has not been determined and 
it is not currently recommended for moderate 
to advanced OSA. Therefore, a pre-operative 
polysomnogram should be obtained to exclude 
underlying moderate to severe OSA. Early data 
has suggested potential success in mild sleep 
apnoea (106). However, the subjective improve- 
ment in snoring should not deter from a repeat 
post-operative polysomnogram in patients with 
documented OSA. Of concern, up to 21% of 
patients with OSA may experience a worsening 
in sleep apnoea after LAUP (106). At present, 
the LAUP candidate should have mostly uvula- 
palate obstruction. Since its introduction, the 
number of therapy sessions to get a desired result 
has decreased. This surgery can be performed in 
the outpatient setting under local anaesthesia. 
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TABLE 1. Predictive value of tests used in selection of uvulopalatopharyngoplasty candidates 
Method Predictor of success 
PPV NPV 
(“W (%I P value* 
Dynamic studies 
During sleep 
Somnofluoroscopyt (93) 
Pharyngeal pressure 
Metes et al. (94) 
Hudgel et al. (95) 
Videoendoscopy (88) 
Cine CT (96) 
Awake 
Miiller manoeuvre 
Sher et al. (97) 
Wittig et aZ.f (98) 
Katsantonis et al. (99) 
Aboussouan et al. (89) 
Static studies (awake) 
CT scan 
3-D CT (100) 
Gislason et al. (101) 
Shepard et al. (102) 
Cephalometry after UPPP (103) 
Oropharyngeal exam (104) 
Frequency spectrum (105) 
Narrowest/lst collapse above C2 
Transpalatal obstruction 
Nasopharyngeal obstruction only 
Uvula-soft palate obstruction 
Velopharyngeal collapse only 
Small airway size 
Normoglossia 
Min. area 20 mm below hard palate 
Posterior airway space >lO mm 
Redundant palate/pharynx 
Absence of large amplitudes 
671- 
33 
57 
86 
- 
73 
@3$ 
33 
78 
- 
79 
50 
100 
33 
78 
91 0.01 
67 1 
43 1 
82 0.01 
- - 
- - 
45 0.30 
77 0.67 
63 0.05 
- - 
44 0.27 
88 0.09 
100 <O.OOl 
44 0.64 
75 0.09 
Adapted with permission from reference 112. 
PPV, positive predictive value (or success rate); NPV, negative predictive value. 
Success is >50% decrease in apnoea-hypopnoea index (OAHI) unless otherwise specified. 
*For difference in success rate between groups defined by the method used. 
“ysuccess is 2 50% decrease in OAHI and a >85% decrease in desaturation events. 
@uccess is >50% decrease in the apnoea index. 
However, certain palatal configurations, irre- 
spective of the magnitude of obstruction, can be 
addressed surgically with LAUP in far less time, 
more safely (under local anaesthesia) and with 
equal anatomic results. Despite these advances, 
LAUP may be subject to the same limitations as 
UPPP concerning the difficulties in identifying 
potential responders with OSA. Given the possi- 
bility of worsening of apnoea (106), and the 
possible decreased nasal mask tolerance in 
patients with palatal surgery (59), further studies 
are necessary before the procedure can be 
recommended for OSA. 
A combination of methods may enhance 
the success rate. As mentioned above, there is 
limited data to suggest that the use of a tongue- 
retaining device may be a useful adjunct to 
UPPP (72). One recent study demonstrated cure 
in seven of nine patients treated with combi- 
nation surgery including UPPP, mandibular 
osteotomy and genioglossus advancement (107). 
Similarly, other studies incorporate a surgical 
protocol tailored to a pre-operative assessment 
of obstruction sites; patients with oropharyngeal 
obstruction underwent UPPP, and patients with 
base of tongue obstruction underwent mandibu- 
lar osteotomy with genioglossus advancement. 
Those with obstruction at both sites underwent 
both procedures (108). The success rate of this 
approach is 67% (108). An additional surgical 
procedure for those who fail may include a 
modified hyoid suspension to result in an 
anterior displacement of the hyoid area (109). 
Maxillofacial surgery with maxillary- 
mandibular advancement osteotomy (MMO) 
shows promising results including cure, even in 
patients who fail other therapies (108,110). The 
procedure compares well to nasal CPAP when 
polysomnographic variables are analysed (108). 
Selection of patients for this procedure is done 
either through a surgical protocol after failure of 
other surgical approaches (108), or by cephalo- 
metric selection of candidates (110). The success 
rate of MM0 is in excess of 95% (108). However, 
this surgery is considerable in magnitude, and 
experience has been limited to only a few centres. 
Tracheostomy bypasses all collapsible seg- 
ments of the upper airway, and therefore is the 
definitive treatment of sleep apnoea. Chin reduc- 
tion may be necessary to prevent occlusion of the 
stoma by redundant tissue. The procedure is 
associated with frequent complications (particu- 
larly in patients with fat necks), as well as 
significant emotional and physical morbidity. 
It is best reserved for patients with serious 
cardiovascular complications of OSA (111). 
Conclusion 
Obstructive sleep apnoea is a prevalent, under- 
recognized, serious and treatable disorder that 
should be considered with a high index of 
suspicion in patients with the appropriate pres- 
entation. The detection of the disease could be 
improved by education of primary care prac- 
titioners, use of models based on clinical data, 
and polysomnography. Past years have seen the 
initial promise and ultimate disappointment in 
some medical and surgical approaches adopted 
in its treatment. Recent techniques have been 
successful in effecting cure (defined here as an 
apnoea index ~10 after intervention) in many 
patients. These include nasal CPAP with 
titration of pressure to adequate levels, oral 
appliances, UPPP in selected patients, UPPP 
with mandibular osteotomy and genioglossus 
advancement, maxillofacial surgery (with 
maxillary, mandibular and hyoid advancement), 
and the choice of last resort, tracheostomy. 
Future advancements may uncover more specific 
pharmacotherapeutic agents, refine existing 
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therapies, improve compliance with established 
modalities such as CPAP, improve selection of 
surgical candidates, and broaden the surgical 
options. 
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